Geza Horvai

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · The Lancet · 2019 · 3.2K citations · Full text

Medicine, Oncology, Cancer Pharmacology +11

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau et al. · The Lancet · 2018 · 1.7K citations · Full text

Medicine, Oncology, Pharmacology +11

Final analysis: A randomized, blinded, placebo (P)-controlled phase III study of adjuvant postoperative lapatinib (L) with concurrent chemotherapy and radiation therapy (CH-RT) in high-risk patients with squamous cell carcinoma of the head and neck (SCCHN).

Kevin J. Harrington, Stéphane Temam, Anil D′Cruz et al. · Journal of Clinical Oncology · 2014 · 26 citations

Medicine, Oncology, Radiation Oncology +17

Formulation of thermoresponsive and bioadhesive gel for treatment of oesophageal pain and inflammation

András Makó, G. Csóka, Eszter Pásztor et al. · European Journal of Pharmaceutics and Biopharmaceutics · 2008 · 16 citations

Nursing, Pharmaceutics, Drug Delivery +11